Peptide Cancer Vaccine Market Space Examined by Kuick Research in New Report Now Available at

15 Feb 2016 • by Natalie Aster

LONDON – Among different forms of cancer treatments comprising monoclonal antibody-based immunotherapy, antibody-drug conjugates (ADCs), dendritic cell cancer vaccines, amid others, peptide cancer vaccines takes up an exclusive position owing to its various inherent benefits associated with its mechanism of action (MoA), its production process and its user-friendly compliance. The first cancer vaccine that was successfully launched in the market was a prostate cancer vaccine – provenge (sipuleucel-T).

With the development of next-gen peptide cancer vaccines such as multivalent long peptides, peptide-pulsed dendritic cell cancer vaccines, hybrid peptide vaccines, peptide cocktail vaccines, and personalised peptide vaccines, among others, a number of challenges related to the cancer immunotherapy need to be addressed. The factors hindering the growth of the peptide cancer vaccine market include the dearth of standardised clinical studies success related parameters, which led to the failures of a lot of clinical trials in the last few years. Additionally, tumour cells are known to evade immune reaction by modulating the immune system, inducing immunological tolerance and initiating the cancer immunoediting process.

The prospects of peptide cancer vaccines look very optimistic due to innovative solutions they offer to a great many unanswered questions in cancer immunotherapy. As the knowledge of antigen, its effect on the immune system’s main components is further discerned, the efficacy of peptide vaccines is sure to increase. Till then, the best way forward for peptide cancer vaccines is to utilise multivalent long peptide sequence which is capable of breaking immune tolerance and providing broad therapeutic action. Meantime, researchers are in need of putting across new clinical trial study parameters in compliance with the cancer vaccine programme.

New study “Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” elaborated by Kuick Research covers the world’s peptide cancer vaccine market space. It provides insights into the MoA of peptide cancer vaccines, describes the need of peptide cancer vaccines, provides the clinical trials efficacy study of synthetic peptide analog obtained from WT1 oncoprotein against acute myeloid leukemia, looks at the broad spectrum action of peptide cancer vaccines against major cancer, sheds light on the recent trends in the market. The report gives an overview of the 41 peptide cancer vaccines in pipeline; analyses peptide cancer vaccine clinical pipeline based on company, indication and stage. It also examines the drivers of, and challenges for peptide cancer vaccines. An evaluation of the competitive landscape is included, with profiles of the top 20 market players.

Report Details:

Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight
Published: February, 2016
Pages: 142
Price: US$ 1,500.00

More studies by the publisher are available at Kuick Research page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970